CN104749381B - Assembling suppresses purposes of the albumen PFN2 in esophagus cancer diagnosis reagent is prepared - Google Patents
Assembling suppresses purposes of the albumen PFN2 in esophagus cancer diagnosis reagent is prepared Download PDFInfo
- Publication number
- CN104749381B CN104749381B CN201510144733.7A CN201510144733A CN104749381B CN 104749381 B CN104749381 B CN 104749381B CN 201510144733 A CN201510144733 A CN 201510144733A CN 104749381 B CN104749381 B CN 104749381B
- Authority
- CN
- China
- Prior art keywords
- pfn2
- patient
- diagnosis
- esophageal carcinoma
- positive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
Abstract
The invention provides a kind of assembling suppresses albumen PFN2 preparing diagnosis and/or the purposes in prognostic evaluation patient with esophageal carcinoma reagent.The present invention carries out immune scoring by PFN2 positive cell numbers, then determines the relation with patient's diagnosis and prognosis by PFN2 positive expressions amount, for aiding in diagnosis and the prognostic evaluation of Kazak ethnic population and Han nationality's patient with esophageal carcinoma.The present invention solves the present situation that patient with esophageal carcinoma diagnosis and prognostic evaluation means lack, there is provided a kind of accurately and rapidly Forecasting Methodology.
Description
Technical field
The invention belongs to field of biology, more particularly to one kind assembling suppression albumen, a kind of specifically assembling suppression
Purposes of the albumen PFN2 in esophagus cancer diagnosis reagent is prepared.
Background technology
The cancer of the esophagus is one of China's common cancer, and numerous studies are proved, regardless of the treatment based on operation still
Treatment based on radiotherapy, TNM stage are the principal elements for affecting cancer of the esophagus survival region.However, being frequently seen in clinic point
Phase identical patient with esophageal carcinoma prognosis is dramatically different, so, it is concluded that the Prognostic Factors beyond certainly existing TNM stage.For
More accurately patient with esophageal carcinoma is diagnosed and prognosis evaluation, so as to optimize individualized treatment, found and diagnosis and prognosis
Related molecular marker is research direction from now on.At present, it is provided that accurately and reliably patient with esophageal carcinoma diagnosis and prognosis are believed
The molecular target of breath is considerably less, and judgment criteria also differs in a jumble, and never normalized research report.
Assembling suppresses albumen (Profilin) to be found in 1976, is one of most important actin binding protein, right
Particularly important in cell movement, cell division, neuron differentiation and synaptic plasticity.Profilin2 (abbreviation PFN2) is
A member of Profilin families, wide expression in nervous system development process.Deng discovery spinal muscular atrophy
(SMA) patient is due to the combination quilt of the micromutation or disappearance caused PFN2 and SMN of survival of motor neurons protein (SMN)
Blocking, promotes the phosphorylation of PFN2 and each target gene of Rho kinases and downstream, causes the regular assembling of actin to be received
To affecting, imply and the feasible means for the treatment of spinal muscular atrophy are likely to become for the interference of PFN2.
In recent years, increasing research shows that PFN2 take part in cell signalling process, and pernicious swollen at some
Exist as key factor in the pathogenic process of knurl.Ma Chunyue etc. has found that for the research of oral squamous cell carcinomas PFN-2 is that one kind can be compared with
Reflect well the tumor marker of squamous carcinoma grade malignancy, and closely related with the overall survival of many Patients With Oral Squamous Cell Carcinomas.
Mouneimne, G. etc. are proved, in breast cancer, mechanism that PFN2 and EVL is relied on by actomyosin contraction is suppressing vesica
Prominent activity and cell movement.The downward of PFN2 and EVL enhances the invasion of breast cancer cell, high invasion and attack with breast cancer and
Poor prognosis is relevant.
Content of the invention
For above-mentioned technical problem of the prior art, the invention provides a kind of assembling suppresses albumen PFN2 preparing food
Purposes in pipe cancer diagnostic reagent, described this purposes solve patient with esophageal carcinoma diagnosis and prognosis information in prior art
Molecular target is considerably less, the technical problem that judgment criteria differs.
The invention provides a kind of assembling suppresses albumen PFN2 preparing diagnosis and/or prognostic evaluation patient with esophageal carcinoma reagent
In purposes.
Further, described patient with esophageal carcinoma is Kazak ethnic population or Han nationality.
The present invention carries out immune scoring by PFN2 positive cell numbers, is then determined by PFN2 positive expressions amount and is suffered from
Person's diagnosis and the relation of prognosis, for aiding in diagnosis and the prognostic evaluation of Kazak ethnic population and Han nationality's patient with esophageal carcinoma.
The present invention is compared with prior art, and its technological progress is significant.The present invention is positive by amynologic index PFN2
Expression aids in the diagnosis of Kazak ethnic population and Han nationality's patient with esophageal carcinoma and prognosis is evaluated, and is to solve patient with esophageal carcinoma
The present situation that diagnosis and prognostic evaluation means lack provides a kind of accurately and rapidly Forecasting Methodology.
Description of the drawings
Fig. 1 shows Han nationality's oesophagus normal epithelial tissues middle section PFN2 under 40 times, 100 times, 200 times of multiplication factors
Positive expression amount.
Fig. 2 shows Han nationality's esophageal precancerous lesion tissue middle section PFN2 under 40 times, 100 times, 200 times of multiplication factors
Positive expression amount.
Fig. 3 shows Han nationality's human esophageal carcinoma PFN2 positive expression amounts under 40 times, 100 times, 200 times of multiplication factors.
Fig. 4 is shown in Han nationality's oesophagus normal epithelial tissues, low level intraepithelial neoplasia (cin), intraepithelial neoplasia and food
The expression and distribution situation of PFN2 in pipe squamous carcinoma tissue.
Fig. 5 is shown in 40 times, 100 times, 200 times of multiplication factor Xia Ha race oesophagus normal epithelial tissues middle section PFN2
Positive expression amount.
Fig. 6 is shown in 40 times, 100 times, 200 times of multiplication factor Xia Ha race human esophageal carcinoma PFN2 positive expression amounts.
Fig. 7 shows the expression and distribution situation of PFN2 in race's oesophagus normal epithelial tissues and esophageal squamous cell carcinoma tissue is breathed out.
Fig. 8 shows the positive expression amount of PFN2 and the relation of patient's prognosis, wherein life cycle of the abscissa for patient, indulges
The overall survival of coordinate patient.
Specific embodiment
Below by specific embodiment and combine accompanying drawing the present invention is expanded on further, but be not intended to limit the present invention.
It is attached that the wax stone of 638 human esophageal carcinomas used by the embodiment of the present invention both is from medical college of Shihezi Univ first
Category hospital cardiothoracic surgery, wherein, Han nationality's tissue samples 412 have follow-up person 47, breathe out race's tissue samples 226.This experiment is led to
Ethics Committee of Guo Liao First Affiliated Hospital, Shihezi University College of Medicine, every patient have all signed Informed Consent Form.
Immunohistochemical method, with reference to Wang Guanghui Identification of MXRA5as a novel in 2013
tissue biomarker for colorectal cancer progression.
Mapping software used is SPSS 17.0, GraphPad Prism v5.0.
In embodiments of the invention, used reagent is shown in Table 1, and major experimental instrument and consumptive material are shown in Table 2, matches somebody with somebody used by experiment
Reagent processed is shown in Table 3.
1 experiment reagent of table
| Title | Company | The place of production |
| Dimethylbenzene | Tianjin Fu Yu Fine Chemical Co., Ltd | China |
| 75% alcohol | Xinjiang Jie Pule bio tech ltd | China |
| 95% alcohol | Xinjiang Jie Pule bio tech ltd | China |
| Absolute ethyl alcohol | Tianjin Fu Yu Fine Chemical Co., Ltd | China |
| Citrate buffer | Beijing Bioisystech Co., Ltd of Zhong Shan Golden Bridge | China |
| PBS phosphate buffers | Beijing Bioisystech Co., Ltd of Zhong Shan Golden Bridge | China |
| 30% hydrogenperoxide steam generator | Chengdu Ke Long chemical reagents factory | China |
| PFN2 mono- resists | Abcam | Britain |
| One anti-dilution | Leica | Germany |
| Envision kits | Beijing Bioisystech Co., Ltd of Zhong Shan Golden Bridge | China |
| DAB developers | Dako | Germany |
| Haematoxylin | Shanghai Bo Gu bio tech ltd | China |
| Neutral gum | Shanghai Yi Yang Instrument Ltd. | China |
2 laboratory apparatus of table and consumptive material
| Title | Company | The place of production |
| Organization chip makes instrument | ALPHELYS | Italy |
| Slicer | Leica | Germany |
| Light microscope | Olympus | Japan |
| 4 DEG C of refrigerators | Haier | China |
| - 20 DEG C of refrigerators | Haier | China |
| Biological ice machine | Beijing Chang Liu scientific instrument Co., Ltd | China |
| Insulating box | Bright Medical Instruments factory forever of Beijing | China |
| Electric drying oven with forced convection | Bright Medical Instruments factory forever of Beijing | China |
| Micro sample adding appliance | Eppendorf | Germany |
| Micro-wave oven | Beautiful | China |
| Ophthalmic tweezers | Sihong Jin Jing Medical Devices Co., Ltd.s | China |
| 1.5ml EP are managed | Axygen | The U.S. |
| Tip heads | Axygen | The U.S. |
| Slide | Citotest Labware Manufacturing Co., Ltd. | China |
| Cover glass | Citotest Labware Manufacturing Co., Ltd. | China |
| Wet box | Safe experiment equipment factory of Haimen City | China |
| Staining rack | Safe experiment equipment factory of Haimen City | China |
3 preparation of reagents of table
Embodiment 1
A kind of cancer of the esophagus amynologic index PFN2 positive expressions amount that passes through aids in Kazak ethnic population and Han nationality's cancer of the esophagus to suffer from
The diagnosis of person and the method evaluated by prognosis, specifically include following steps：
(1) 638 human esophageal carcinoma samples of surgery excision are carried out FFPE, makes 638 human esophageal carcinomas
Wax stone；
(2) organization type is determined according to HE dyeing, chooses tumor tissues and be fabricated to organization chip；Above-mentioned organization chip is existed
Olympus optical microphotograph Microscopic observations, choose center of tumor position and are shot, seen respectively under 40,100 and 200 times
Examine, it can be seen that PFN2 is in Partial tumors central authorities positive expression, and expression is higher, concrete as shown in Figure 3；PFN2 is before cancer
Pathological tissues positive expression, expression are of a relatively high, concrete as shown in Figure 2；Can also be observed that PFN2's in normal structure
Positive expression, at the basal cell that positive expression now is often confined to, concrete such as Fig. 1.
In sum, the positive expression of PFN2 is very special, and positive expression in most esophageal cancer cells, in pole
Be negative in the esophageal cancer cell of minority expression, thus this experiment can more accurately obtain the positive expression situation of PFN2,
So as to carry out following survival Analysis, as a result accurately credible, i.e., the positive staining of PFN2 is concentrated mainly on tumour cell karyon
And endochylema, the coloring of tumor tissues interstitial is seldom.
(3) wax stone of histotomy is made 4 μm of serial section, the histotomy of gained is placed on metallochromy frame
On, it is positioned in 65 DEG C of baking ovens that to bake piece 30 minutes paraffin melting to surface；
(4) histotomy routine dewaxing aquation：
Organization chip sequentially passes through dimethylbenzene and embathes 3 times × 5 minutes；Absolute ethyl alcohol embathes 1 time, 5 minutes；90% alcohol soaks
Wash 1 time, 5 minutes,；80% alcohol embathes 1 time, 5 minutes；70% alcohol embathes 1 time, 5 minutes, makes the paraffin on histotomy surface
Take off and abundant aquation, slide is put in water and embathes 3 times；
(5) hot repair of high pressure antigen is multiple；During histotomy is dipped in by 1 × citrate buffer, high fire in micro-wave oven
Shelves heating 3 minutes；Taking-up is put into pressure cooker, and 1300W is heated to jet, and 800W is reheated 10 minutes；Cool down under room temperature after taking-up,
Section is put in water embathes 3 times；
(6) deactivating endogenous peroxydase：30 minutes in 3% hydrogenperoxide steam generator, then histotomy is immersed in
Histotomy is put in water and embathes 3 times；
(7) histotomy is placed in vibration washing 3 times × 5 minutes in 1 × PBS, and unnecessary PBS bufferings wiped by blotting paper
Liquid.
(8) it is added dropwise one to resist：PFN2 mono- anti-(ab55611, Abcam) presses 1 with an anti-dilution:400 dilutions；It is placed in wet box
4 DEG C of overnight incubations；Negative control replaces one to resist with PBS；
(9) wet box, rewarming 15 minutes are taken out；PBS vibration washings 3 times × 5 minutes；Unnecessary PBS wiped by blotting paper；
(10) it is added dropwise two to resist：The universal immunologic combined detection reagent kit of anti-rabbit/mouse (PV-6000), hereinafter referred to as two anti-examinations
Agent box, every histotomy are added dropwise the 75 μ l of A liquid in two anti-kits, 37 DEG C of incubations 30 minutes；
(11) DAB colour developings：PBS embathes 3 times × 5 minutes, two anti-kits be in stoste and buffer solution according to stoste:Dilute
Liquid is released for 1：100 proportional arrangement adds the nitrite ion of 100 μ l into nitrite ion, every histotomy, controls under the microscope aobvious
The color time, observe positive findings occur again without stopped reaction during obvious background coloration, with distilled water flushing 5 minutes；
(12) haematoxylin redyes 3 minutes；Histotomy is put in water and embathes 3 times；Sour alcohol breaks up 0.5s, and histotomy is put
Enter；Running water oil blackeite 5 minutes；
(13) it is dehydrated and transparent：Histotomy is sequentially passed through 70% alcohol and embathes 1 time, 5 minutes；80% alcohol embathes 1
Secondary, 5 minutes；Absolute ethyl alcohol embathes 1 time, 5 minutes；Dimethylbenzene embathes 3 times, every time 5 minutes；
(14) mounting：Place 5 minutes in fume hood, make the dimethylbenzene on histotomy volatilize, then sealed with neutral gum
Piece, places 1 hour after mounting in baking oven, natural gum is solidified as early as possible；
(15) with Olympus light microscopes at a 200-fold magnification, using double scoring semiquantitative method scorings：Such as table 4
It is shown,<5% cell positive is 0 point；6%-25% cell positives are 1 point；26%-50% cell positives are 2 points；51%-75%
Cell positive is 3 points；>75% cell positive is 4 points.Coloring degree presses the presence or absence of cell colour developing and depth scoring：Cell is without aobvious
Color is 0 point；Light yellow is 1 point；Brown color is 2 points；Sepia is 3 points.Then in conjunction with positive cell percentage and tinctorial strength
Be multiplied classification, and obatained score is 0-1 timesharing, is classified as (-)；2-4 point is (+)；5-8 point is (++)；9-12 point is (+++).Its
In-it is feminine gender；+ it is weakly positive；++/+++ is strong positive.
Table 4
The scoring distribution situation of the human esophageal carcinoma of 47 above-mentioned follow-ups is shown in Table 5.
| Immunity scoring | Number of cases | Percentage |
| 0 point | 5 | 10.6% |
| 2 points | 2 | 4.3% |
| 3 points | 6 | 12.7% |
| 4 points | 8 | 17.0% |
| 6 points | 2 | 4.3% |
| 8 points | 17 | 36.2% |
| 12 points | 7 | 14.9% |
Table 5
(16) according to the histological type of sample, the human esophageal carcinoma sample of Han nationality is divided into normal epithelial tissues, rudimentary
Other intraepithelial neoplasia (cin) tissue, intraepithelial neoplasia tissue and squamous carcinoma tissue, each group scoring are shown in Table 6.
Table 6
(17) GraphPad Prism v5.0 mapping softwares are utilized, by Han nationality's human esophageal carcinoma sample in step (16)
The immunity scoring of patient is mapped as ordinate, is organized according in the figure of gained as abscissa by histological type
Learn the relation of type and immunity scoring to judge the diagnosis effect of PFN2 positive expressions amount and patient with esophageal carcinoma, can from Fig. 1～4
To judge, the high Han nationality patient of PFN2 positive expression amounts is diagnosed as esophageal squamous cell carcinoma or the possibility of precancerous lesion is bigger.
(18) according to the histological type of sample, the human esophageal carcinoma for breathing out race is divided into normal epithelial tissues and squamous carcinoma group
Knit, each group scoring is shown in Table 7.
Table 7
(19) GraphPad Prism v5.0 mapping softwares are utilized, by race of step (18) China and Kazakhstan human esophageal carcinoma sample
The immunity scoring of patient is mapped as ordinate, is organized according in the figure of gained as abscissa by histological type
Learn the relation of type and immunity scoring to judge the diagnosis effect of PFN2 positive expressions amount and patient with esophageal carcinoma, can from Fig. 5～7
To judge, the possibility that the high Kazakhstan race patient of PFN2 positive expression amounts is diagnosed as esophageal squamous cell carcinoma is bigger.
(20) according to the immunity scoring of step (15), by immunity scoring<4 points are classified as one group, i.e. PFN2 positive expressions amount
Low one group；Immunity scoring is classified as one group for >=4 points, i.e. high one group of PFN2 positive expressions amount；
(21) SPSS17.0 mapping softwares are utilized, by the one group and PFN2 positive that PFN2 positive expression amounts are low in step (20)
The overall survival of patient is carried out as ordinate by the patient survival that the follow-up of expression high a group is obtained as abscissa
Mapping, judges that according to the figure life cycle of gained and the relation of overall survival PFN2 positive expression amounts are pre- with patient with esophageal carcinoma
Effect, may determine that from Fig. 8 afterwards, and the low patient survival of PFN2 positive expression amounts is long, good prognosis；PFN2 positive expression amounts
High patient survival is short, poor prognosis.
As can be seen that the diagnosis and prognosis of the low patient of PFN2 positive expression amounts are positive significantly better than PFN2 from Fig. 7～8
The high patient of expression, i.e., relatively low PFN2 positive expressions amount are closely related with patient preferably diagnosis and prognosis.
In sum, the present invention is that a kind of amynologic index PFN2 positive expressions amount that passes through aids in Kazak ethnic population and the Chinese
The diagnosis of race's patient with esophageal carcinoma and the purposes evaluated by prognosis, i.e., according to PFN2 positives table in patient with esophageal carcinoma tumor tissues
Height up to rate directly determines diagnosis and the prognosis information of patient.
The above is only the citing of embodiments of the present invention, it is noted that for the ordinary skill of the art
For personnel, on the premise of without departing from the technology of the present invention principle, some improvement can also be made, these improvement also should be regarded as this
The protection domain of invention.
Claims (1)
1. a kind of detection assembling suppresses the reagent of albumen PFN2 expressions preparing patient with esophageal carcinoma diagnosis and/or prognostic evaluation examination
Purposes in agent, it is characterised in that：The patient with esophageal carcinoma is Han Nationalities in Xinjiang patient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510144733.7A CN104749381B (en) | 2015-03-30 | 2015-03-30 | Assembling suppresses purposes of the albumen PFN2 in esophagus cancer diagnosis reagent is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510144733.7A CN104749381B (en) | 2015-03-30 | 2015-03-30 | Assembling suppresses purposes of the albumen PFN2 in esophagus cancer diagnosis reagent is prepared |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104749381A CN104749381A (en) | 2015-07-01 |
| CN104749381B true CN104749381B (en) | 2017-03-15 |
Family
ID=53589370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510144733.7A Expired - Fee Related CN104749381B (en) | 2015-03-30 | 2015-03-30 | Assembling suppresses purposes of the albumen PFN2 in esophagus cancer diagnosis reagent is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104749381B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107802838A (en) * | 2017-09-25 | 2018-03-16 | 石河子大学 | PLCE1 inhibitor combines the application in the medicine for preparing treatment esophageal squamous cell carcinoma with NF κ B pathway inhibitors |
| CN109541213A (en) * | 2018-11-23 | 2019-03-29 | 新乡医学院 | A kind of cancer of the esophagus kit for screening |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2295602B1 (en) * | 2005-07-27 | 2012-07-11 | Oncotherapy Science, Inc. | Method of prognosing cancers |
| CN101365806B (en) * | 2005-12-01 | 2016-11-16 | 医学预后研究所 | For identifying method and apparatus and the purposes of prediction curative effect thereof of the biomarker of therapeutic response |
-
2015
- 2015-03-30 CN CN201510144733.7A patent/CN104749381B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN104749381A (en) | 2015-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105233304B (en) | Applications of the long-chain non-coding RNA LOC553103 on nasopharyngeal carcinoma cell inhibitor is prepared | |
| CN108169490B (en) | Combined protein for evaluating prognosis of glioblastoma and application thereof | |
| He et al. | Expression of nestin in ovarian serous cancer and its clinicopathologic significance. | |
| CN104749381B (en) | Assembling suppresses purposes of the albumen PFN2 in esophagus cancer diagnosis reagent is prepared | |
| CN107422123B (en) | It is a kind of for diagnosing the kit of oral squamous cell carcinoma | |
| CN106908609A (en) | Purposes of the tumour-specific trnaplantation antigen albumen TSTA3 in oesophagus squama cancer diagnosis reagent is prepared | |
| CN105200156B (en) | Long-chain non-coding RNA LOC553103 application | |
| CN107966566A (en) | A kind of kit for being used to detect Xinjiang region patients with esophageal squamous cell carcinoma outcome | |
| CN116165383A (en) | Endometrial cancer diagnosis marker and application thereof | |
| CN109022585A (en) | PBLD gene is preparing the application in clear cell carcinoma of kidney diagnosis and prediction prognosis drug | |
| CN105200155B (en) | The application of the microRNA BART6-3p of Epstein-Barr virus coding | |
| CN105267987B (en) | Applications of the long-chain non-coding RNA LOC553103 on stomach cancer cell inhibitor is prepared | |
| CN114622014A (en) | Application of PCP4 as tumor differentiation marker of neuroblastoma | |
| Zhai et al. | The relationship between the expressions of tumor associated fibroblasts Cav-1 and MCT4 and the prognosis of papillary carcinoma of breast. | |
| CN101995475A (en) | Method for diagnosing breast cancer by expression of SOX2 protein | |
| CN105112524A (en) | Reagent kit based on CDC27 (complement dependent cytotoxicity 27) genes and used for auxiliary diagnosis and/or prognosis judgment on colorectal cancer | |
| CN105497916B (en) | Small molecule non-coding RNA miR-125b is preparing the application in the drug for treating the wrap-around vascular group liver cancer of tumour | |
| CN108977545A (en) | A kind of ovarian cancer diagnosis or prognostic portfolio object and its application | |
| CN110441523A (en) | ATAD2 albumen is judging the application in oophoroma vegetative state as marker | |
| WO2023217035A1 (en) | Use of reagent for detecting c1qbp protein expression level in preparation for oral cancer screening or prognosis kit | |
| CN107779509A (en) | A kind of mark of pulmonary cancer diagnosis and its application | |
| CN113416704B (en) | Primary cells and progeny cells of human renal vascular smooth muscle lipoma and application of primary cells and progeny cells | |
| Zong et al. | Expression and significance of Caspase-8 in non-small cell lung cancer (NSCLC) | |
| CN108125976A (en) | Predict brain metastasis molecular marked compound miR-4270 and the application in drug and diagnostic kit | |
| Muhammad et al. | MicroRNAs in Lung Cancer tissues and Pleural fluids: A Review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170315 Termination date: 20210330 |